IAVI policy brief examines HIV vaccine funding

NewsGuard 100/100 Score

A new policy brief from the International AIDS Vaccine Initiative (IAVI) "summarizes data on HIV vaccine R&D funding trends originally published by the HIV Vaccines and Microbicides Resource Tracking Working Group in 2011," according to the IAVI website. "The crucial addition of a preventive HIV vaccine to [a comprehensive biomedical HIV prevention] toolkit will not only depend on the sustained commitment of current donors. It will also depend on the support of a diversified field of new champions willing to fund the research required to capitalize on new discoveries in the HIV vaccine field," the brief states, noting that "[b]etween 2009 and 2010, overall investment in HIV vaccine R&D dropped one percent from $868 million to $859 million" (November 2011).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel vaccine approach targets AML and other blood cancers